DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial

被引：9
|
作者：
Klempner, Samuel J.
Chao, Joseph
Uronis, Hope Elizabeth
Sirard, Cynthia A.
Kagey, Michael
Baum, Jason
Song, James
Wang, Jin
Kim, In-Ho
Lee, Keun Wook
Oh, Do-Youn
Sonbol, Bassam Bassam
Wainberg, Zev A.
Ajani, Jaffer A.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Duke Univ, Durham, NC USA
[4] HeathCare Pharmaceut Inc, Cambridge, MA USA
[5] Leap Therapeut Inc, Cambridge, MA USA
[6] BeiGene, Beijing, Peoples R China
[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[10] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med,Canc Res Inst, Seoul, South Korea
[11] Mayo Clin Arizona Phoenix, Div Hematol Oncol, Canc Ctr, Phoenix, AZ USA
[12] UCLA Med Ctr Santa Monica, Santa Monica, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292
引用
收藏
页数：4
相关论文
共 50 条
  • [1] DKN-01 and tislelizumab plus chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
    Klempner, S. J.
    Chao, J.
    Uronis, H.
    Sirard, C.
    Kagey, M.
    Baum, J.
    Song, J.
    Wang, J.
    Sonbol, M. B.
    Wainberg, Z. A.
    Ajani, J. A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1103 - S1104
  • [2] DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
    Klempner, S. J.
    Sirard, C.
    Chao, J.
    Chiu, V.
    Mahalingam, D.
    Uronis, H.
    Kagey, M.
    Baum, J.
    Dayyani, F.
    Song, J.
    Wang, J.
    Iqbal, S.
    Tejani, M.
    Sonbol, M. B.
    Scott, A. J.
    Wainberg, Z.
    Ajani, J. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1048 - S1049
  • [3] A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA)
    Klempner, Samuel J.
    Sonbol, Bassam Bassam
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Chiu, Vi Kien
    Scott, Aaron James
    Iqbal, Syma
    Tejani, Mohamedtaki Abdulaziz
    Stilian, Melissa C.
    Thoma, Mathis
    Kagey, Michael
    Baum, Jason
    Sirard, Cynthia A.
    Altura, Rachel A.
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
    Pelster, Meredith
    Strickler, John H.
    Sirard, Cynthia A.
    Baum, Jason
    Haas, Mike
    Devoe, Craig E.
    Bustamante, Liliana
    Bubis, Jeffrey Alan
    Womack, Mark Sanders
    Wainberg, Zev A.
    Chung, Ki Y.
    Raff, Joshua P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 104 - 104
  • [5] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
    Lee, Keun-Wook
    Moehler, Markus H.
    Cunningham, David
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Oh, Do-Youn
    Kim, In-Ho
    Shim, Byoung Yong
    Sym, Sun Jin
    Altura, Rachel A.
    Stilian, Melissa C.
    Parker, Elizabeth C.
    Klempner, Samuel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484
  • [6] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Ku, G.
    Elimova, E.
    Denlinger, C. S.
    Mehta, R.
    Lee, K-W.
    Iqbal, S.
    Kang, Y-K.
    Oh, D-Y.
    Rha, S. Y.
    Kim, Y. H.
    Seol, Y. M.
    Mwatha, T.
    Grim, J.
    Ajani, J. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045
  • [7] Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).
    Pal, Sumanta K.
    Sonpavde, Guru
    Agarwal, Neeraj
    Vogelzang, Nicholas J.
    Srinivas, Sandy
    Haas, Naomi B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial
    Vaishampayan, U. N.
    Schoffski, P.
    Ravaud, A.
    Borel, C.
    Song, T.
    Guenther, S.
    Grewal, J.
    Gulley, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [9] Patterns of care in renal cell carcinoma (RCC): Impact of duration of first-line (1L) treatment on second-line (2L) treatment choice
    Feinberg, Bruce A.
    Garofalo, David
    Drenning, Jason
    Montgomery, Jim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial
    Chung, Hyun Cheol
    Arkenau, Hendrik-Tobias
    Lee, Jeeyun
    Rha, Sun Young
    Oh, Do-Youn
    Wyrwicz, Lucjan
    Kang, Yoon-Koo
    Lee, Keun-Wook
    Bauer, Todd M.
    Lee, Sung Sook
    Kemeny, Margaret
    Keilholz, Ulrich
    Melichar, Bohuslav
    Mita, Alain
    Plummer, Ruth
    Smith, Denis
    Gelb, Arnold B.
    Xiong, Huiling
    Hong, Janet
    Chand, Vikram
    Safran, Howard
    [J]. CANCER RESEARCH, 2018, 78 (13)
12345